Pioglitazone

ArticlesMedicine Compliance Aid StabilityLactation Safety InformationNew Medicines ·
326058001

Articles

Medicine Compliance Aid Stability

ActosTakeda UK Ltd

Takeda UK Ltd
Actos
Tablets 15mg, 30mg, 45mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage
23 January 2015

Lactation Safety Information

Insulin, metformin or alternative approropriate antidiabetic drug
No published evidence of safety
18 September 2020

New Medicines

Sudden sensorineural hearing loss (SSNHL) in adults - intratympanic gel and modified-release tablet

Information

New formulation
Strekin AG
Strekin AG

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Jan 21Development discontinued as the phase 3 study with pioglitazone in hearing loss was negative. Company has no plans to bring this treatment to the market [10].

Category

PPAR (peroxisome proliferator-activated receptor)-gamma agonist
SSNHL incidence varies from 5 to 30 cases per 100,000 per year, although one European study estimated 160 per 100,000 per year. Applying this figure to the 2017 mid‐year population, the estimated incidence of SSNHL in England and Wales is from 2,937 to 17,623 per year [1].
Sudden sensorineural hearing loss (SSNHL) in adults - intratympanic gel and modified-release tablet
Oral and
Intratympanic

Evidence based evaluations